Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1999 1
2001 1
2003 4
2004 2
2005 1
2006 2
2007 2
2008 4
2009 5
2010 5
2011 10
2012 5
2013 7
2014 4
2015 5
2016 2
2017 7
2018 7
2019 11
2020 8
2021 10
2022 10
2023 12
2024 12
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHERINE Study Group. Geyer CE Jr, et al. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070. N Engl J Med. 2025. PMID: 39813643 Clinical Trial.
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn J, Teixeira de Sousa R, Brufsky AM, O'Brien CS, Schmitt F, Higgins G, Varghese D, James GD, Moh A, Livingston A, de Giorgio-Miller V. Viale G, et al. Among authors: basik m. ESMO Open. 2023 Aug;8(4):101615. doi: 10.1016/j.esmoop.2023.101615. Epub 2023 Aug 8. ESMO Open. 2023. PMID: 37562195 Free PMC article.
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, Wagner LI, Sledge GW. Khan SA, et al. Among authors: basik m. J Clin Oncol. 2022 Mar 20;40(9):978-987. doi: 10.1200/JCO.21.02006. Epub 2022 Jan 7. J Clin Oncol. 2022. PMID: 34995128 Free PMC article. Clinical Trial.
3D chromatin remodeling potentiates transcriptional programs driving cell invasion.
Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, McCaffrey L, Deblois G, Kleinman C, Park M, Basik M, Witcher M. Lebeau B, et al. Among authors: basik m. Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2203452119. doi: 10.1073/pnas.2203452119. Epub 2022 Aug 29. Proc Natl Acad Sci U S A. 2022. PMID: 36037342 Free PMC article.
Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.
Rezoug Z, Totten SP, Szlachtycz D, Atayan A, Mohler K, Albert S, Feng L, Lemieux Anglin B, Shen Z, Jimenez D, Hamel N, Meti N, Esfahani K, Boileau JF, Prakash I, Basik M, Meterissian S, Tremblay F, Fleiszer D, Anderson D, Chong G, Wong SM, Foulkes WD. Rezoug Z, et al. Among authors: basik m. JAMA Netw Open. 2024 Sep 3;7(9):e2431427. doi: 10.1001/jamanetworkopen.2024.31427. JAMA Netw Open. 2024. PMID: 39226054 Free PMC article.
Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy.
Farncombe KM, Wong D, Norman ML, Oldfield LE, Sobotka JA, Basik M, Bombard Y, Carile V, Dawson L, Foulkes WD, Malkin D, Karsan A, Parkin P, Penney LS, Pollett A, Schrader KA, Pugh TJ, Kim RH; CHARM consortium. Farncombe KM, et al. Among authors: basik m. Am J Hum Genet. 2023 Oct 5;110(10):1616-1627. doi: 10.1016/j.ajhg.2023.08.014. Am J Hum Genet. 2023. PMID: 37802042 Free PMC article. Review.
Federated Deep Learning Enables Cancer Subtyping by Proteomics.
Cai Z, Boys EL, Noor Z, Aref AT, Xavier D, Lucas N, Williams SG, Koh JMS, Poulos RC, Wu Y, Dausmann M, MacKenzie KL, Aguilar-Mahecha A, Armengol C, Barranco MM, Basik M, Bowman ED, Clifton-Bligh R, Connolly EA, Cooper WA, Dalal B, DeFazio A, Filipits M, Flynn PJ, Graham JD, George J, Gill AJ, Gnant M, Habib R, Harris CC, Harvey K, Horvath LG, Jackson C, Kohonen-Corish MRJ, Lim E, Liu JJ, Long GV, Lord RV, Mann GJ, McCaughan GW, Morgan L, Murphy L, Nagabushan S, Nagrial A, Navinés J, Panizza BJ, Samra JS, Scolyer RA, Souglakos J, Swarbrick A, Thomas D, Balleine RL, Hains PG, Robinson PJ, Zhong Q, Reddel RR. Cai Z, et al. Among authors: basik m. Cancer Discov. 2025 Sep 4;15(9):1803-1818. doi: 10.1158/2159-8290.CD-24-1488. Cancer Discov. 2025. PMID: 40488620 Free PMC article.
Histology agnosticism: Infra-molecularizing disease?
Campbell J, Cambrosio A, Basik M. Campbell J, et al. Among authors: basik m. Stud Hist Philos Sci. 2024 Apr;104:14-22. doi: 10.1016/j.shpsa.2024.02.002. Epub 2024 Feb 19. Stud Hist Philos Sci. 2024. PMID: 38377771 Free article.
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Denkert C, Lambertini C, Fasching PA, Pogue-Geile KL, Mano MS, Untch M, Wolmark N, Huang CS, Loibl S, Mamounas EP, Geyer CE, Lucas PC, Boulet T, Song C, Lewis GD, Nowicka M, de Haas S, Basik M. Denkert C, et al. Among authors: basik m. Clin Cancer Res. 2023 Apr 14;29(8):1569-1581. doi: 10.1158/1078-0432.CCR-22-1989. Clin Cancer Res. 2023. PMID: 36730339 Free PMC article.
132 results